Journal
The GLP-1 Pipeline, August 2026: Every Drug Worth Watching, One Honest Page
Released: Last reviewed:
The short answer
Five stories define the late-2026 pipeline. Retatrutide (Lilly, GLP-1/GIP/glucagon triple): the ceiling-setter at roughly 24% in phase 2, phase-3 TRIUMPH program running — the successor most worth the wait nobody should actually wait for. CagriSema (Novo, semaglutide + amylin analog): roughly 22.7% in phase 3, famously short of its own 25% guidance, submissions advancing. Orforglipron (Lilly, small-molecule pill): roughly 12.4% phase 3, no needle, no fasting ritual, factory-scale manufacturing — the access revolution wearing modest efficacy. Survodutide (Boehringer, GLP-1/glucagon): up to ~19% obesity, headline MASH results, phase 3 underway. Amycretin and the amylin wave (Novo and others): early-phase double-digit results in compressed timeframes — promising, immature. Approval status: orforglipron was approved by the FDA on April 1, 2026 and is sold as Foundayo; the other four: none. Legal purchase lane: none. The standing sentence: today's approved 15–21% at $129–$449 beats tomorrow's 24% at undefined, and switching later is a prescription refill, not a life decision.
How to read every future readout
Four filters keep pipeline news useful. Phase and endpoint: phase-2 percentages routinely shrink in phase 3 (broader populations, stricter analyses — CagriSema's arc is the case study); biopsy-confirmed liver endpoints outrank MRI fat fractions; 72-week results outrank 24. Cross-trial humility: comparing one drug's trial to another's is squinting, not science — only head-to-heads (SURMOUNT-5, SURPASS-2) settle rankings, and the pipeline has run none against the incumbents yet. The price silence: no pipeline drug has announced pricing, and the class's history (this site's price-history essay) says launch lists start high and channels evolve — the next drugs' relevance to a budget buyer arrives years after their approval headlines. The gray-market constant: every named molecule above is already sold by research-chemical sites — no approval, no compounding legality (the FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page, current as of October 1, 2026, states retatrutide and cagrilintide cannot be used in compounding under federal law), no oversight — and every one of those listings is the same scam wearing a newer name. What actually changes for a 2026 patient when a readout drops: nothing, until approval, pricing, and coverage exist; what changes then: a conversation with a prescriber who can map your current dose onto the new option in one visit. Treat now. Switch later, if later earns it. The tracker updates when the facts do.
Questions people ask
What's the strongest weight-loss drug in the pipeline?
Retatrutide's ~24% phase-2 result is the studied ceiling (phase-3 TRIUMPH running), with CagriSema's ~22.7% phase-3 close behind. Neither is approved; cross-trial comparisons are squinting until head-to-heads run; and phase-3 numbers historically shrink from phase-2 highs.
Should I wait for the next generation instead of starting now?
No — the standing arithmetic: approved drugs deliver 15–21% today at known prices ($129–$449 across channels), pipeline drugs deliver nothing until approval plus pricing plus coverage exist (years, historically), and switching later is routine. Waiting costs treatable months for a marginal, unpriced future gain.
Can I buy retatrutide, CagriSema, or orforglipron anywhere now?
Only as gray-market research chemicals — unapproved, no legal compounding lane, no quality oversight, real safety risk. Every legitimate version of these drugs arrives through approval and pharmacies, announced loudly; everything before that wearing their names is the same scam, renamed.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.